Tygh Capital Management’s NovoCure NVCR Stock Holding History

Tygh Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-51,600	Closed	-$3.48M	–	86
2020 Q1	$3.48M	Buy	51,600 +20,753	+67%	+$1.64M	0.78%	54
2019 Q4	$2.6M	Buy	+30,847	New	+$2.49M	0.43%	72
2019 Q1	–	Sell	-127,973	Closed	-$4.29M	–	85
2018 Q4	$4.29M	Sell	127,973 -86,458	-40%	-$3.16M	0.9%	50
2018 Q3	$11.2M	Sell	214,431 -36,338	-14%	-$1.45M	1.84%	12
2018 Q2	$7.85M	Buy	+250,769	New	+$6.98M	1.33%	29

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Tygh Capital Management's NVCR Position: Q2 2020 in Review

Tygh Capital Management sold out of NovoCure (NVCR) in Q2 2020, closing a stake of 51,600 shares — an estimated $3.48M sold.

Tygh Capital Management first reported a position in NVCR in Q2 2018 and held it in 5 quarters. The position peaked at $11.2M in Q3 2018. 264 funds tracked by Wall St. Rank hold NVCR as of Q2 2020.

Tygh Capital Management reported no remaining NovoCure position as of Q2 2020 after selling out during the quarter.
Tygh Capital Management sold 51,600 NovoCure shares in Q2 2020, an estimated $3.48M.
Tygh Capital Management first reported a position in NovoCure in Q2 2018 and held it in 5 quarters.
Tygh Capital Management's NovoCure position peaked at $11.2M in Q3 2018.
264 funds tracked by Wall St. Rank held NovoCure as of Q2 2020.

Based on Tygh Capital Management's 13F filing for Q2 2020, filed 5 Aug 2020.